Cytiva expands portfolio with new MabSelect Resins made from renewable agarose for scalable, cost-efficient mAb manufacturing Read more
Global divide emerges among physicians over patient choice in biologics vs. biosimilars, reveals GlobalData Read more
Biocon Biologics announces positive results from Phase 3 Study of Yesintek biosimilar to Ustekinumab for chronic plaque psoriasis Read more
Biocon Biologics finalises agreement for Bmab 1200 market entry in Europe, UK, Canada, and Japan Read more